SCHEMBL20459002

SCHEMBL20459002

CCC[C@H](CC)c1ccc(C)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.38
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
SLC6A2 P23975 3/20 0.35
SLC6A3 Q01959 3/20 0.35
SLC6A4 P31645 2/20 0.35
HPGD P15428 2/20 0.33
NPC1 O15118 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NR1I2 O75469 1/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
AGTR1 P30556 1/20 0.33
EPHX2 P34913 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20032302 0.89 CYP3A4 (0.43) CYP3A4ESR1ESR2SLC6A2SLC6A3
SCHEMBL21164366 0.86 S1PR1 (0.36) ESR1ESR2SLC6A2SLC6A3SLC6A4
SCHEMBL257515 0.81 AGTR1 (0.42) SLC6A2SLC6A3SLC6A4HPGDSMN1; SMN2
SCHEMBL27472082 0.81 SLC6A2 (0.40) CYP3A4SLC6A2SLC6A3SLC6A4KDM4E
SCHEMBL21164367 0.79 LMNA (0.39) ESR1ESR2NR1I2ALDH1A1
SCHEMBL20289179 0.78 TAS1R3 (0.47) HPGDCYP2C9CYP2C19MAPTTAS1R3
SCHEMBL19003642 0.78 ESR1 (0.37) ESR1ESR2SLC6A2SLC6A3SLC6A4
SCHEMBL21164523 0.77 SLC6A4 (0.36) CYP3A4ESR1ESR2SLC6A2SLC6A3
SCHEMBL21125000 0.77 AKR1C3 (0.38)
SCHEMBL21164590 0.77 MAPT (0.42) NPC1CYP1A2CYP2C19RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2719384-B1 Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders OTSUKA AMERICA PHARMACEUTICAL INC (US) 2018-08-08 EP disclosed